LONDON — Novo Nordisk’s new CEO dismissed on Wednesday that his firm’s try and outflank Pfizer for the weight problems startup Metsera may run into regulatory points, and argued that the corporate’s provide mirrored its “bolder” strikes to develop its pipeline.
“If we didn’t really feel that we might be capable to shut the deal, we might not have most likely entered the transaction,” Mike Doustdar, who took over as CEO in August, instructed reporters on a name tied to the corporate’s third quarter earnings report.
But when Novo’s transfer to outbid Pfizer is being considered as a extra aggressive stance for the Danish pharma, it additionally displays the crunch that Doustdar and the corporate discover themselves in, as development of their weight problems and diabetes merchandise slows and as rival Eli Lilly elbows it out in market share. Its inventory worth is down about 50% this 12 months.
This text is unique to STAT+ subscribers
Unlock this text — plus every day protection and evaluation of the pharma trade — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.